Biotech Values

[dewophile]

it certainly doesnt seem like ribavirin will be needed when the phase 3 data come out in this subtype
i wonder if ENTA can use this data to argue that the non-nuke has a minimal contribution to efficacy in pts with 1b (and aim for a higher royalty share)